Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical, pathological, and oncological outcomes in unclassified renal cell carcinoma compared to clear cell renal cell carcinoma.
Indian J Urol
January 2025
Department of Urology, Cancer Institute of the State of São Paulo, São Paulo, Brazil.
Purpose: This study aims to assess the impact of unclassified renal cell carcinoma (uRCC) on clinical, pathological, and oncological outcomes compared with clear cell renal cell carcinoma (ccRCC).
Materials And Methods: We analyzed the data of 48 uRCC and 688 ccRCC cases, collected from a histopathological database at a single center from July 2011 to August 2019. uRCC cases were confirmed according to the 2016 World Health Organization classification.
Resection and Reconstruction of the Inferior Vena Cava Using a Tunneled Peritoneal Graft for Renal Tumor With Thrombus: Venous Compensation via the Azygos Vein Following Early Graft Occlusion.
Cureus
December 2024
Surgery, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma De Nuevo León, Monterrey, MEX.
Inferior vena cava (IVC) invasion by tumor thrombus poses a significant surgical challenge, often requiring vascular reconstruction. Standard methods, including prosthetic and autologous vein grafts, have limitations such as infection risks, anticoagulation demands, and increased costs. We present the case of a 66-year-old male with a right renal tumor (T3bN0M0, Neves Zincke II) and gross hematuria, who underwent radical nephrectomy with open thrombectomy.
View Article and Find Full Text PDFImmune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas.
Cancers (Basel)
January 2025
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). Clear cell RCC is the predominant subtype, representing about 70-80% of all RCC cases, while non-clear cell subtypes collectively make up the remaining 20-30%.
View Article and Find Full Text PDFPersisting challenges in the development of predictive biomarkers for immuno-oncology therapies for renal cell carcinoma.
Expert Rev Anticancer Ther
January 2025
Department of Urology, Iwate Medical University, Shiwa, Iwate, Japan.
Introduction: Immuno-oncology (IO) therapies have become integral to renal cell carcinoma (RCC) management, RCC remains a complex malignancy with diverse clinical behaviors and a heterogeneous tumor microenvironment, highlighting the need for predictive biomarkers to optimize therapy.
Areas Covered: This review synthesizes recent findings from clinical trials, translational studies, and molecular analyses to provide an updated perspective on biomarker research for IO therapies in RCC. A literature search was conducted using PubMed, Embase, and Web of Science for articles published between January 2010 and November 2024.
Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential.
Cancer Treat Res Commun
January 2025
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address:
Clear cell renal cell carcinoma (ccRCC) poses a significant global health challenge as its incidence continues to rise, resulting in a substantial annual mortality rate. Major clinical challenges to current ccRCC treatments include high drug-resistance rates as well as dose-limiting adverse events; underlining the need to identify additional 'druggable' targets. TGF-β1, VEGF, and PD-L1 are potential therapeutic targets in ccRCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!